Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Bernstein BruceOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Boctor FadyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,533Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Boctor FadyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:49,645Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Walker Wayne RemellOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Arnold MitchellOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Silverman JoshuaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Bradley GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
Filings by filing date
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Bernstein BruceOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Boctor FadyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,533Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Boctor FadyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:49,645Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Walker Wayne RemellOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Arnold MitchellOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Silverman JoshuaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Dec 21, 2023 (filed on Dec 26, 2023)Insider Name:Bradley GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1185 Avenue Of The Americas 3Rd Floor, Suite 570 NEW YORK NY 10036 |
Tel: | N/A |
Website: | https://www.petrospharma.com |
IR: | See website |
Key People | ||
John D. Shulman Executive Chairman of the Board | Fady Boctor President, Chief Commercial Officer | Mitchell Arnold Chief Accounting Officer, Vice President - Finance |
Business Overview |
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac. |
Financial Overview |
For the fiscal year ended 31 December 2023, Petros Pharmaceuticals Inc revenues decreased 3% to $5.8M. Net loss applicable to common stockholders decreased 31% to $13.8M. Revenues reflect Prescription Medications segment decrease of 16% to $2.3M, United States segment decrease of 6% to $4.5M. Lower net loss reflects Intangible asset impairment decrease from $7.5M (expense) to $0K, Selling. |
Employees: | 21 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $5.82M as of Dec 31, 2023 |
EBITDA (TTM): | -$10.33M as of Dec 31, 2023 |
Net annual income (TTM): | -$13.81M as of Dec 31, 2023 |
Free cash flow (TTM): | -$7.63M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 6,875,814 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |